US Patent

US9872854 — Methods for the treatment of psoriatic arthritis using apremilast

Method of Use · Assigned to Celgene Corp · Expires 2034-05-29 · 8y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

Methods of treating, managing or preventing psoriatic arthritis are disclosed. Specific methods encompass the administration of apremilast, alone or in combination with a second active agent.

USPTO Abstract

Methods of treating, managing or preventing psoriatic arthritis are disclosed. Specific methods encompass the administration of apremilast, alone or in combination with a second active agent.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2232 — Otezla
U-2232 — Otezla
U-2232 — Otezla

Patent Metadata

Patent number
US9872854
Jurisdiction
US
Classification
Method of Use
Expires
2034-05-29
Drug substance claim
No
Drug product claim
No
Assignee
Celgene Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.